Dr. Shea Talks About Pulmonary Fibrosis Research

Dr. Shea Talks About Pulmonary Fibrosis Research

As a serious, rare and deathly disease with no known cure, pulmonary fibrosis research is always evolving in an attempt to discover new treatment options, medicines or therapies that can help improve PF patients life and extend life expectancy. Researchers and doctors are in constant work to develop treatment…

5 Tips to Manage Breathlessness and Coughing

https://www.youtube.com/watch?v=IHMy1kOoAm8 Pulmonary fibrosis is a lung condition that causes scaring of the lung tissue which results in difficulties in breathing. In this video, shared by the Royal Society of Medicine, you can watch a lecture by Dr. Sharon Chadwick where she shares some tips on…

6 Ways to Diagnose Pulmonary Fibrosis

Pulmonary fibrosis is a disease that affects the respiratory system by the thickening and stiffening of lung tissue, which ends up as scar tissue.  In cases when physicians are unable to identify the root cause of the disease, it is called idiopathic pulmonary fibrosis. There is no single test that is able to…

Compound in Traditional Chinese Medicine Seen to Block Lung Fibrosis in Mice

Salvianolic acid B, a compound isolated from red sage and a main component of the traditional Chinese medicine known as Yiqihuoxue formula, prevented fibrotic changes both in bleomycin-treated mice and in cell culture models. These findings indicate the compound may be worth exploring as a less toxic alternative to treating fibrosis. Traditional Chinese medicine is…

Living with Idiopathic Pulmonary Fibrosis: Patient Story

https://www.youtube.com/watch?v=sz-iLi-B3Gg Pulmonary fibrosis is a lung disease that causes the scarring of the lungs, resulting in breathing difficulties. The condition can affect anyone, at any age, although the patients most at risk are usually older patients. Unfortunately, up until now there is still no cure for pulmonary fibrosis but there…

Merck Acquires Afferent, and Potential Treatments for Chronic Cough, for $500M

Merck is acquiring Afferent Pharmaceuticals — including its therapeutic candidates targeting the P2X3 receptor, now in clinical testing for neurogenic conditions that include chronic respiratory diseases — under a definitive agreement announced by the two companies. A lead investigational drug developed by Afferent, AF-219, is under evaluation in a Phase 2b dose-escalating study (…

Your PF Community

Woman laying down reading

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

View Forums